Cognitive Research Corporation

Executive Summary

Cognitive Research Corporation (CRC) is a specialized contract research organization (CRO) focused exclusively on central nervous system (CNS) clinical trials. Founded in 2006 and headquartered in San Francisco, CRC leverages over 20 years of deep CNS expertise to deliver science-led neuroscience studies. The company differentiates itself through consistent clinical teams and a tailored strategic approach, addressing the high complexity and failure rates inherent in CNS drug development. By maintaining dedicated teams across trials, CRC reduces variability and improves data quality, a critical advantage in indications such as Alzheimer's, Parkinson's, and depression. Although CRC is currently in the pre-clinical stage as a service provider, its established reputation and niche focus position it well within the growing CNS therapeutics market, which is expanding due to aging populations and increased neurological disease prevalence. CRC's business model relies on securing contracts with pharmaceutical and biotech sponsors. The company faces competition from larger full-service CROs but counters with specialized expertise and a track record of efficient trial execution. Key growth drivers include the rising demand for CNS therapies, regulatory tailwinds for neurodegenerative disease trials, and potential expansion into digital biomarkers. While no recent funding rounds or financial disclosures are available, CRC's longevity suggests stable operations. The company's private status limits visibility, but its domain expertise and consistent team strategy represent a defensible niche. Conviction is moderate, reflecting the lack of public catalysts and the competitive landscape.

Upcoming Catalysts (preview)

• Q3 2026Major Pharma Partnership for CNS Trial60% success
• Q4 2026Launch of Digital Endpoint Platform50% success
• Q2 2026Series A Funding Round70% success